July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Photochemical antimicrobial therapy for keratitis with an improved riboflavin conjugate (BPerox) for highly resistant bacteria in vitro
Author Affiliations & Notes
  • Lorena Zendejas Reyes
    ASOCIACION PARA EVITAR LA CEGUERA EN MEXICO, Ciudad de M?xico, DF, Mexico
  • Andreina Tarff
    Ophthalmology , The Wilmer Ophthalmological Institute, JHU, Baltimore, Maryland, United States
  • Rebecca Yee
    Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, Maryland, United States
  • Ying Zhang
    Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, Maryland, United States
  • Ashley Behrens
    Ophthalmology , The Wilmer Ophthalmological Institute, JHU, Baltimore, Maryland, United States
  • Footnotes
    Commercial Relationships   Lorena Zendejas Reyes, None; Andreina Tarff, None; Rebecca Yee, None; Ying Zhang, None; Ashley Behrens, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3656. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lorena Zendejas Reyes, Andreina Tarff, Rebecca Yee, Ying Zhang, Ashley Behrens; Photochemical antimicrobial therapy for keratitis with an improved riboflavin conjugate (BPerox) for highly resistant bacteria in vitro. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3656.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The combination of riboflavin (RF) and ultraviolet light A (UVA) is an antimicrobial strategy centered on electron transfer and generation of reactive oxygen. Hydrogen peroxide acts as an oxidizing and a reducing agent that could maximize RF redox potential. The purpose of this study is to evaluate the bactericidal efficacy of BPerox, a novel light-sensitive phototherapy molecule.

Methods : Carbapenemase producing Klebsiella pneumonia (CPKP), fluoroquinolones-resistant Acinetobacter baumannii (FRAB) and multidrug-resistant Escherichia coli (MDREC) (107 CFU/ml) were exposed in 12-well culture plates to BPerox, a light sensitive compound containing RF + hydrogen peroxide 0.004%. Two treatment plans according to the dose were established: A) BPerox 0.1% - 0.004% photoactivated by 3 mW/cm2 for 30 min and B) BPerox 0.5% - 0.004% photoactivated by 10 mW/cm2 UVA for 10 min, both at a wavelength of 365 nm through an 8-mm optic aperture. In addition, wild type Pseudomonas aeruginosa (PA) (105 CFU/ml) biofilms were grown on soft hydrogel contact lenses, and after 12-h incubation, planktonic cells were removed by three washes in phosphate buffered saline (PBS). BPerox-UVA regimens A and B were administered and sonication was applied after 12-h incubation to separate the biofilm from the lenses surface. For all bacteria, serially diluted samples were plated and incubated overnight to enumerate cell survival (CFU/ml). Controls and triplicate values were obtained. Data was analyzed using unpaired t-test.

Results : BPerox-UVA treatment plans produced complete bacterial sterilization (0 CFU/ml) on CPKP, FRAB and MDREC. Treatments A and B for RF + UVA and hydrogen peroxide +UVA resulted in at least 106 CFU/ml (p ≤ 0.0005). The untreated sample and single treatments with BPerox, RF, UVA and hydrogen peroxide resulted in at least 108 CFU/ml (p ≤ 0.0001). BPerox-UVA photoactivation consistently killed all (0 cell/ml) PA biofilms by using treatment doses A and B, and controls showed consistently more bacteria 106-109 CFU/ml (p ≤ 0.0004).

Conclusions : BPerox photochemical therapy exhibited 100% killing activity against highly resistant bacteria in vitro and was capable of disrupting the bacterial biofilm architecture.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×